



### The effects of *Lactobacillus reuteri* probiotics combined with azithromycin on peri-implantitis: A randomized placebo-controlled study

Tada H, Masaki C, Tsuka S, Mukaibo T, Kondo Y, Hosokawa R.


J Prosthodont Res. online 26 Jul 2017. pii: S1883-1958(17)30074-9. doi: 10.1016/j.jpor.2017.06.006

#### Demonstrated significant clinical benefits of *L. reuteri* Prodentis as an adjunct to antibiotic treatment of peri-implantitis

#### Results

- Pocket probing depth (PPD) was significantly improved in the *L. reuteri* Prodentis group at week 4 and 24 compared to week 0 ( $p < 0.05$ ). This did not occur in the placebo group
- Modified bleeding index (mBI) was significantly lower at week 24 in the *L. reuteri* Prodentis group compared to placebo ( $p < 0.05$ )

#### Comparison of PPD for implants



#### Conclusion

- *L. reuteri* Prodentis may provide effective adjunctive therapy of peri-implantitis

#### Facts

- Study design: randomized, double blind, placebo-controlled clinical trial with *L. reuteri* Prodentis as an adjunct to initial treatment with azithromycin (500 mg/day for 3 days)
- Subjects: 30 adults with mild to moderate peri-implantitis, mean age 67 years
- Dosage: 1 lozenge daily ( $2 \times 10^8$  CFU/day)
- Duration: antibiotic treatment for 3 days followed by probiotic treatment for 24 weeks
- Primary endpoint: PPD
- Secondary endpoints: BOP, mPI, mBI, and bacterial numbers

#### Further reading

- Flichy-Fernández AJ et al. The effect of orally administered probiotic *Lactobacillus reuteri*-containing tablets in peri-implant mucositis: a double-blind randomized controlled trial. J Periodontol Res. 2015;50:775-785
- Vivekananda MR et al. Effect of the probiotic *Lactobacillus reuteri* (Prodentis) in the management of periodontal disease: a preliminary randomized clinical trial. J Oral Microbiol. 2010;2:5344-5352
- Vicario M et al. Clinical changes in periodontal subjects with the probiotic *Lactobacillus reuteri* Prodentis: a preliminary randomized clinical trial. Acta Odontol Scand. 2013;71:813-19

BioGaia can not be held responsible for any inconsistency of this material with local laws and regulations or any incorrect translations of the original version produced in English.

BioGaia AB, Kungsbrogatan 3, P.O. Box 3242, SE-103 64 Stockholm, Sweden, +46 (0)8 555 293 00, biogaia.com

**BioGaia**<sup>®</sup>  
Probiotics grounded in evolution  
Driven by science